Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Scientists: Zika outbreak to end in two to three years

The Zika outbreak rampaging through Latin America will likely burn itself out in the next two to three years, based on the fact that people develop immunity to the virus after an initial infection, British scientists said.

Read More »

For the first time, scientists to sequence genes in space

Tests are intended to prove whether genomic technology can be used to understand microbes in the International Space Station, to scan astronauts for genetic changes that could diagnose illness, and in future missions, potentially to test samples from Mars and elsewhere for signs of DNA-based life.

Read More »

FDA Hits DMD Drugmaker Santhera With Lengthy Delay

The FDA does not support Santhera Pharmaceuticals’ plan to file an NDA for Raxone (idebenone) under subpart H for Duchenne muscular dystrophy (DMD) patients not using concomitant glucocorticoids.

Read More »

Merck Plans to Open Microbiome R&D Site in Former Idenix Facility in Cambridge

Merck’s Cambridge, Mass., microbiome R&D site will be located in the 50,000 square foot complex formerly owned by Idenix Pharmaceuticals, a company Merck snapped up in 2014.

Read More »

Gilead Avoided Paying $10 Billion in 2015 Taxes

Gilead Sciences was able to avoid paying billions in 2015 taxes thanks to loopholes in the law, StatNews reported.

Read More »

Study casts doubt on ‘obesity paradox’

Being overweight or obese is linked to a higher risk of dying prematurely than being normal weight and the risk rises sharply as the extra pounds pile on, scientists said.

Read More »

Antipsychotic drug also relieves nausea from cancer chemotherapy

Adding the cheap antipsychotic drug olanzapine to conventional anti-vomiting medicine can help prevent nausea in cancer patients, according to a new test of 380 volunteers.

Read More »

UCLA study finds why some cancers stop responding to immunotherapy

Researchers have for the first time identified mechanisms that enable advanced melanoma to become resistant to a new class of drugs, known as immunotherapies, which work by enlisting the body’s own immune system to fight the disease.

Read More »

U.S. health spending to rise 5.8% a year through 2025

Healthcare spending in the United States will likely grow by an average 5.8 percent per year over the next decade according to updated projections from the federal government.

Read More »

GE aims for $1 billion cell therapy ‘tools’ business

GE’s healthcare unit aims to build a $1 billion business offering vital manufacturing tools for a coming wave of cell therapies, helped by the acquisition of a Swiss firm.

Read More »

Pfizer Shows Off Final Data from Two Late-Stage Dermatitis Studies

Detailed results from Pivotal Phase 3 studies (AD-301 and AD-302) showed that crisaborole achieved statistically significant results on primary and secondary endpoints for the treatment of atopic dermatitis (AD) in children 2 years of age and up and adults versus vehicle ointment alone.

Read More »

Merck & Co. to Cut or Shift 360 East Coast Jobs, Add 100 in the Bay Area

Merck & Co. announced that it is cutting R&D jobs at three locations on the East Coast: Kenilworth and Rahway, New Jersey, and North Wales, Pennsylvania.

Read More »

Faslodex U.S. patent litigation resolved

AstraZeneca has entered into an agreement with Sandoz, the generic pharmaceuticals division of Novartis, to resolve Faslodex patent litigation in the U.S.

Read More »

Shares of Juno Therapeutics jump after FDA removes clinical hold on cancer drug trial

Juno Therapeutics Inc. said U.S. health regulators have removed a clinical hold on its cancer drug trial that was put in place following the death of three patients.

Read More »

FDA panel backs Amgen copy of AbbVie arthritis drug Humira

Amgen Inc.’s cheaper version of AbbVie’s top-selling arthritis drug Humira is highly similar to the original and should be approved, an advisory panel to the U.S. Food and Drug Administration concluded.

Read More »

FDA expands use of Pfizer’s best-selling pneumonia vaccine

FDA expanded the use of Pfizer’s best-selling pneumonia vaccine Prevnar to adults aged 18 through 49.

Read More »

PPD drug succeeds in mid-stage study

Sage Therapeutics Inc. said its lead drug alleviated symptoms of severe postpartum depression, meeting the main goal of a small mid-stage study.

Read More »

Bayer, X-Chem Expand Drug Discovery Collaboration to Discover Novel Medicines

Bayer and X-Chem Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, have entered into an expanded global drug discovery collaboration across multiple therapeutic areas and target classes.

Read More »

Evelo and Epiva Biosciences Merge

Evelo BioSciences and Epiva Biosciences will combine efforts to become a leading immuno-microbiome platform company in the U.S.

Read More »

U.S. approves Shire’s keenly awaited eye drug

Shire won U.S. approval for its most important new medicine, a treatment for dry eyes, in a fresh boost for the company which completed its $32 billion acquisition of U.S. rare diseases specialist Baxalta in June.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2018 Focus: Top 50 Pharma, Company of the Year and more!


Ad Right Bottom